The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.